Acute Coronary Syndrome - Pipeline Insight, 2025

This “Acute Coronary Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Acute Coronary Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Acute Coronary Syndrome: Understanding

Acute Coronary Syndrome: Overview

The term acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial ischemia and covers the spectrum of clinical conditions ranging from unstable angina (UA) to non - ST-segment elevation myocardial infarction (NSTEMI) to ST-segment elevation myocardial infarction (STEMI). Unstable angina and NSTEMI are closely related conditions: their pathophysiologic origins and clinical presentations are similar, but they differ in severity. A diagnosis of NSTEMI can be made when the ischemia is sufficiently severe to cause myocardial damage that results in the release of a biomarker of myocardial necrosis into the circulation (cardiac-specific troponins T or I, or muscle and brain fraction of creatine kinase [CK-MB]). In contrast, the patient is considered to have experienced UA if no such biomarker can be detected in the bloodstream hours after the initial onset of ischemic chest pain. Unstable angina exhibits 1 or more of 3 principal presentations: (1) rest angina (usually lasting >20 minutes), (2) new-onset (< 2 months previously) severe angina, and (3) a crescendo pattern of occurrence (increasing in intensity, duration, frequency, or any combination of these factors).

Atherosclerosis is the ongoing process of plaque formation that involves primarily the intima of large- and medium-sized arteries; the condition progresses relentlessly throughout a person's lifetime, before finally manifesting itself as an acute ischemic event. Several coronary risk factors influence this process, including hypercholesterolemia, hypertension, diabetes, and smoking. These risk factors damage the endothelium of the blood vessel and result in endothelial dysfunction, which plays a pivotal role in initiating the atherosclerotic process. A dysfunctional endothelium is characterized by reduced bioavailability of nitric oxide and by excessive production of endothelin 1, which impairs vascular hemostasis; increased expression of adhesion molecules (eg, selectins, vascular cell adhesion molecules, and intercellular adhesion molecules); and increased thrombogenicity of blood through the secretion of several locally active substances.

The symptoms of UA/NSTEMI and STEMI are similar, and differentiating the two requires medical evaluation and 12-lead electrocardiography (ECG). The 2007 guidelines for managing UA/NSTEMI, released by the American College of Cardiology (ACC) and the American Heart Association (AHA), state that patients with symptoms suggestive of ACS should be instructed to call 9-1-1 and should be referred to a facility that has capabilities for 12-lead ECG recording, biomarker determination, and evaluation by a physician (eg, an emergency department [ED]).

'Acute Coronary Syndrome- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Coronary Syndrome pipeline landscape is provided which includes the disease overview and Acute Coronary Syndrome treatment guidelines. The assessment part of the report embraces, in depth Acute Coronary Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Coronary Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Coronary Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Coronary Syndrome.

Acute Coronary Syndrome Emerging Drugs Chapters

This segment of the Acute Coronary Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Coronary Syndrome Emerging Drugs

Dalcetrapib : DalCor Pharmaceuticals

Dalcetrapib is a modest CETP inhibitor that in early human studies demonstrated dose-dependent increases in HDL cholesterol levels of up to 30% and no LDL cholesterol lowering. While producing similar increases in larger, cholesterol-rich particles as other CETP inhibitors, dalcetrapib also generated lipid-depleted pre-β-HDL particles, suggesting a potential effect on HDL remodeling in addition to its effect of impeding exchange of lipid species. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Acute Coronary Syndrome.

Acute Coronary Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Acute Coronary Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Coronary Syndrome

• There are approx. 4+ key companies which are developing the therapies for Acute Coronary Syndrome. The companies which have their Acute Coronary Syndrome drug candidates in the most advanced stage, i.e. Phase III include, DalCor Pharmaceuticals.

Phases

The report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Coronary Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Coronary Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Coronary Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Coronary Syndrome drugs.

Acute Coronary Syndrome Report Insights

• Acute Coronary Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Coronary Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Coronary Syndrome drugs?
• How many Acute Coronary Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Coronary Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Coronary Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Coronary Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Janssen Research & Development, LLC
• DalCor Pharmaceuticals
• Hyloris Pharmaceuticals

Key Products

• Milvexian
• Dalcetrapib
• HY-074

This product will be delivered within 2 business days.